Pharmacodynamics of Kardos Administered as Monotherapy and in Combination with Hypothiazide and Enalapril in Grade I-II Arterial Hypertension

@article{Petrov2009PharmacodynamicsOK,
  title={Pharmacodynamics of Kardos Administered as Monotherapy and in Combination with Hypothiazide and Enalapril in Grade I-II Arterial Hypertension},
  author={V. I. Petrov and Oleg Iliich Epshtein and Svetlana Alexandrovna Sergeeva and P. A. Bakumov and E. A. Zernyukova and Yu. A. Zabolotneva and M. V. Kachanova and L. B. Sabanov},
  journal={Bulletin of Experimental Biology and Medicine},
  year={2009},
  volume={148},
  pages={335-336}
}
Therapy with kardos produced an antiihypertensve effect in patients with grade I-II arterial hypertension. This antiihypertensve effect was considerably potentiated, when kardos was administered in combination with enalapril. 
[The phenomenon of release activity and the hypothesis of "spatial" homeostasis].
  • O. Epstein
  • Biology
    Uspekhi fiziologicheskikh nauk
  • 2013
TLDR
It was shown that dilutions of parent substance prepared using this technology have one common peculiarity - they are capable to exert direct modifying effect on parent substance altering spatial structure ofparent substance and consequently its physical, chemical and biological properties.

References

SHOWING 1-3 OF 3 REFERENCES
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
TLDR
The most effective therapy prescribed by the most careful clinician will control hypertension only if patients are motivated, and empathy builds trust and is a potent motivator.
First Expert Report of Scientifi c Society for Arterial Hypertension , All - Russian Cardiological Society and Interdepartmental Council on Cardiovalcular Diseases ( DAH 1 )
  • Klin . Farmakol . Ter .
  • 2003
Results of 24-h BP monitoring and Echocardiography in Groups of Patients before and after 6-Week Therapy (M±m) Parameter Initial After 6-week therapy % of initial Group 1 SBP, mm Hg 150.1±2.9
  • Klin. Farmakol. Ter.,
  • 2000